Trial
NCT04480086
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AbbVie
Collaborators
—
Condition
Myelofibrosis (MF)
Intervention
Mivebresib
Why stopped
Strategic considerations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-29